RT Journal Article
SR Electronic
T1 Prognostic whole-genome and transcriptome signatures in colorectal cancers
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.03.28.23287846
DO 10.1101/2023.03.28.23287846
A1 Nunes, Luís
A1 Li, Fuqiang
A1 Wu, Meizhen
A1 Luo, Tian
A1 Hammarström, Klara
A1 Lundin, Emma
A1 Ljuslinder, Ingrid
A1 Mezheyeuski, Artur
A1 Edqvist, Per-Henrik
A1 Löfgren-Burström, Anna
A1 Zingmark, Carl
A1 Edin, Sofia
A1 Larsson, Chatarina
A1 Mathot, Lucy
A1 Osterman, Erik
A1 Osterlund, Emerik
A1 Ljungström, Viktor
A1 Neves, Inês
A1 Yacoub, Nicole
A1 Guðnadóttir, Unnur
A1 Birgisson, Helgi
A1 Enblad, Malin
A1 Ponten, Fredrik
A1 Palmqvist, Richard
A1 Uhlén, Mathias
A1 Wu, Kui
A1 Glimelius, Bengt
A1 Lin, Cong
A1 Sjöblom, Tobias
YR 2023
UL http://medrxiv.org/content/early/2023/03/30/2023.03.28.23287846.abstract
AB Colorectal cancer (CRC) is caused by a sequence of somatic genomic alterations affecting driver genes in core cancer pathways1. To understand the functional and prognostic impact of cancer-causing somatic mutations, we analysed the whole genomes and transcriptomes of 1,063 primary CRCs in a population-based cohort with long-term follow-up. From the 96 mutated driver genes, 9 were novel to CRC and 24 to any cancer. Two distinct patterns of pathway co-mutations were observed, timing analyses identified 6 early and 3 late driver gene mutations, and several new signatures of CRC specific mutational processes were uncovered. Mutations in 10 protein-coding genes belonging to the WNT, EGFR, and TGF-β pathways, 2 mitochondrial DNA genes and 3 regulatory elements along with the COSMIC SBS44 signature impacted survival. Gene expression classification yielded 5 prognostic subtypes with distinct molecular features, in part explained by underlying genomic alterations. Microsatellite instable tumours could be divided in two classes with different levels of hypoxia and infiltration of immune and stromal cells. This study constitutes the largest integrated genome and transcriptome analysis of CRC to date, and links mutations, gene expressions and patient outcomes. The identification of prognostic mutations and expression subtypes can guide future efforts to individualize CRC therapy.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by the Swedish Cancer Society (CAN 2018/772 and 21 1719 Pj to TS and 22 2054 Pj 01H to BG), the Uppsala Cancer Foundation to BG and by the Guangdong Provincial Key Laboratory of Human Disease Genomics (2020B1212070028). The U-CAN project, and part of this study, was funded by a grant from the Swedish Government (CancerUU) to Uppsala University, Umeå University, KTH Royal Institute of Technology, and Stockholm University (2010-ongoing), and grants from the Erling-Persson Foundation to TS and MU.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Sampling and analyses were performed under the ethical permits Uppsala EPN 2004-M281, 2010-198, 2007-116, 2012-224, 2015-419, 2018-490, and Umeå EPN 2016-219 and EPM 2019-566.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAccess to raw data and more detailed clinical information can be sought by contacting U-CAN (https://www.u-can.uu.se/?languageId=1). The remaining data are available within the Article, Supplementary Information or available from the authors upon request.